Skip to content
by Legal Desire
21 July 2020

Latham & Watkins Advises Tizona Therapeutics in Acquisition by Gilead Sciences

Advising firms

Deal team

19 lawyers named
LawyerFirmSeniorityPracticeOffice
Mark Bekheit Lead Latham & Watkins LLP Partner corporate Bay Area
Brett Urig Latham & Watkins LLP Associate corporate Orange County
Michelle Lu Latham & Watkins LLP Associate corporate Bay Area
Raul Gonzalez Latham & Watkins LLP Associate corporate Bay Area
Christopher Lim Latham & Watkins LLP Associate corporate Bay Area
Judith Hasko Latham & Watkins LLP Partner general corporate Bay Area
Ben Potter Latham & Watkins LLP Partner general corporate Bay Area
Jekkie Kim Latham & Watkins LLP Associate intellectual property Bay Area
Peggy Ni Latham & Watkins LLP Associate intellectual property Bay Area
Ashley Wagner Latham & Watkins LLP Partner benefits and compensation Bay Area
James Robinson Latham & Watkins LLP Associate benefits and compensation Bay Area
Ben Haas Latham & Watkins LLP Partner regulatory Washington, D.C.
Nathan Beaton Latham & Watkins LLP Associate regulatory Not stated
Betty Pang Latham & Watkins LLP Counsel healthcare and privacy Bay Area
Heather Deixler Latham & Watkins LLP Counsel healthcare and privacy Not stated
Kirt Switzer Latham & Watkins LLP Partner tax Bay Area
Lauren Bewley Latham & Watkins LLP Associate tax New York
Mandy Reeves Latham & Watkins LLP Partner antitrust Washington, D.C.
Patrick English Latham & Watkins LLP Counsel antitrust Not stated

Stated terms

Stated value
USD 300m ($300 million)
What the figure measures
Total transaction value
Client
Tizona Therapeutics Inc.Sell-side
Counterparties
Gilead Sciences, Inc. (Buy-side)